GGrantIndex
← Leaderboards

Roderick O'Sullivan

University Of Pittsburgh At Pittsburgh

$5,003,277
Attributed
$5,003,277
Total exposure
2
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $831.7K · FY201625
$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$5,003,277 · 2

By mechanism

R01$5,003,277 · 2

Top collaborators

No co-investigators on record.

Most similar at University Of Pittsburgh At Pittsburgh

Same institution · by research overlap

Others in their field

Top investigators on “Detection

Research focus

DetectionTelomere PathwayMolecularTelomere MaintenanceTelomereStructureMaintenanceMalignant NeoplasmsMutationRegulationResponseRepairedAffectDna DamageChromatinInnovationCellsBypassCancer CellChromatin ModelingChromosomesProteomicsPublic Health RelevanceAtrx Gene

Grant awards (13)

Co-Regulation of Alternative Lengthening of Telomeres and Chromatin Dynamics in ATRX-DAXX deficient cancer cells$463,559
R01 · FY2025 · CA · contact PI
Inhibition of the ALT pathway by interfering with Poly-ADP-Ribose metabolism$368,160
R01 · FY2025 · CA · contact PI
Co-Regulation of Alternative Lengthening of Telomeres and Chromatin Dynamics in ATRX-DAXX deficient cancer cells$440,381
R01 · FY2024 · CA · contact PI
Inhibition of the ALT pathway by interfering with Poly-ADP-Ribose metabolism$349,752
R01 · FY2024 · CA · contact PI
Co-Regulation of Alternative Lengthening of Telomeres and Chromatin Dynamics in ATRX-DAXX deficient cancer cells$447,821
R01 · FY2023 · CA · contact PI
Inhibition of the ALT pathway by interfering with Poly-ADP-Ribose metabolism$360,797
R01 · FY2023 · CA · contact PI
Co-Regulation of Alternative Lengthening of Telomeres and Chromatin Dynamics in ATRX-DAXX deficient cancer cells$456,960
R01 · FY2022 · CA · contact PI
Inhibition of the ALT pathway by interfering with Poly-ADP-Ribose metabolism$368,160
R01 · FY2022 · CA · contact PI
Inhibition of the ALT pathway by interfering with Poly-ADP-Ribose metabolism$349,004
R01 · FY2020 · CA · contact PI
Inhibition of the ALT pathway by interfering with Poly-ADP-Ribose metabolism$338,612
R01 · FY2019 · CA · contact PI
Inhibition of the ALT pathway by interfering with Poly-ADP-Ribose metabolism$349,164
R01 · FY2018 · CA · contact PI
Inhibition of the ALT pathway by interfering with Poly-ADP-Ribose metabolism$349,240
R01 · FY2017 · CA · contact PI
Inhibition of the ALT pathway by interfering with Poly-ADP-Ribose metabolism$361,667
R01 · FY2016 · CA · contact PI